INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $50 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $28 | $0 | $0 | $0 |
| Gross Profit | -$28 | $0 | $50 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $4,887 | $5,804 | $7,639 | $7,353 |
| G&A Expenses | $0 | $2,253 | $2,316 | $2,114 |
| SG&A Expenses | $2,518 | $2,253 | $2,316 | $2,114 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $16,514 | $0 | $0 |
| Operating Expenses | $7,405 | $24,571 | $9,955 | $9,467 |
| Operating Income | -$7,433 | -$24,571 | -$9,905 | -$9,467 |
| % Margin | – | – | -19,810% | – |
| Other Income/Exp. Net | $961 | $113 | $166 | $249 |
| Pre-Tax Income | -$6,472 | -$24,458 | -$9,739 | -$9,218 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,472 | -$24,458 | -$9,739 | -$9,218 |
| % Margin | – | – | -19,478% | – |
| EPS | -0.24 | -1.05 | -0.43 | -0.41 |
| % Growth | 77.1% | -144.2% | -4.9% | – |
| EPS Diluted | -0.24 | -1.05 | -0.43 | -0.41 |
| Weighted Avg Shares Out | 26,585 | 23,298 | 22,496 | 22,280 |
| Weighted Avg Shares Out Dil | 26,585 | 23,298 | 22,496 | 22,280 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $28 | $0 | $0 | $0 |
| EBITDA | -$6,444 | -$8,057 | -$9,905 | -$9,218 |
| % Margin | – | – | -19,810% | – |